

NDA 201280/S-025 NDA 201281/S-031

SUPPLEMENT APPROVAL

Boehringer Ingelheim Pharmaceuticals, Inc. Attention: My Tran, PharmD Post-Doctoral Fellow, Regulatory Affairs 900 Ridgebury Road, PO Box 368 Ridgefield, CT 06877

Dear Dr. Tran:

Please refer to your supplemental new drug applications (sNDAs) dated and received September 17, 2021, and your amendments, submitted under section 505(b) and pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tradjenta (linagliptin) tablets and Jentadueto (linagliptin and metformin hydrochloride) tablets, respectively.

These Prior Approval sNDAs provide for multiple labeling updates to the Prescribing Information and Medication Guide of Tradjenta and Jentadueto. The proposed changes also include reordering of 'Heart Failure' in section 5 Warnings and Precautions in the Prescribing Information.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual

¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm



NDA 201280/S-025 NDA 201281/S-031 Page 2

reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS


Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.





NDA 201280/S-025 NDA 201281/S-031 Page 3

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michael Oyewole, Regulatory Project Manager, at (301) 796-3897.

Sincerely,

{See appended electronic signature page}

Patrick Archdeacon, M.D.
Associate Director for Therapeutics
Division of Diabetes, Lipid Disorders, and Obesity
Office of Cardiology, Hematology, Endocrinology,
and Nephrology
Center for Drug Evaluation and Research

ENCLOSURES:

 Content of Labeling (Prescribing Information and Medication Guide) for Tradjenta and Jentadueto



This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

PATRICK ARCHDEACON 04/15/2022 02:40:48 PM

